Brain Metastases

Promising Results Reported from Xcytrin Phase III Trial for Brain Tumors

Published in Cancer Weekly, November 7th, 2000

Pharmacyclics, Inc. (PCYC) reported results from the lead-in phase of its ongoing randomized Phase III clinical trial of Xcytrin (motexafin gadolinium) Injection for the treatment of cancer patients with brain metastases.

The company also reported promising preliminary results from an ongoing Phase I safety trial of Xcytrin for treatment of glioblastoma multiforme (i.e., primary brain tumors). These results were presented at the 42nd Annual Meeting of the American Society for Therapeutic Radiology and Oncology (ASTRO), held in Boston, Massachusetts, during October 2000.

"Xcytrin appeared to improve local control in the brain, with very few patients...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (2000-11-07)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry